D-threonine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: D-threonine
• 英文别名: (2R)-2-azaniumyl-3-hydroxybutanoate
• 化学式: C₄H₉NO₃
• 分子量: 119.12
• InChiKey: AYFVYJQAPQTCCC-ZJRLKYRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  D-threonine 在 盐酸 作用下， 以 甲醇 为溶剂， 生成 D-threonine methyl ester hydrochloride
  参考文献：
  名称：

  Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II

  摘要：

  一种化合物，是一种公式（I）的苯并[a]菲啉-11-甲酰胺衍生物，其中R1至R4中的每一个，它们相同或不同，被选择为氢、卤素、羟基、未取代或取代的C1-C6烷氧基、杂环氧基、未取代或取代的C1-C6烷基、硝基、氰基、叠氮基、酰肼基、CO2R10、CON(R12)2、OCON(R12)、SR10、SOR11、SO2(R11)、SO2N(R12)2、N(R12)2、NR10SO2R11、N(SO2R11)2NR10(CH2)nCN、NR10COR11、OCOR11或COR10；R5至R7中的每一个，它们相同或不同，被选择为氢、卤素、羟基、C1-C6烷氧基、C1-C6烷基、SR10和N(R12)2；Q是未取代或取代的C1-C6烷基，其被（i）未取代或取代的C1-C6烷基，（ii）羟基、前提是羟基不是在公式（I）中与Q相邻的任一N原子，（iii）CO2R10，或（iv）CON(R12)所取代；R1和R9，它们相同或不同，分别是氢或C1-C6烷基，或R8和R9连同它们连接到的氮原子形成饱和的5-或6-成员N-含杂环戊或六元环，可能包括一个额外的由O、N和S中选择的杂原子，或R8和R9中的一个是由O、N或S随机中断的烷基链，它连接到由Q表示的烷基链上的碳原子，以完成上述定义的饱和的5-或6-成员N-含杂环戊或六元环；或其药学上可接受的盐；但至少一个R1到R4不是氢。这些化合物是拓扑异构酶I和/或拓扑异构酶II的抑制剂，可用于治疗肿瘤，包括表达MDR的肿瘤。

  公开号：

  US20030139409A1
• 作为产物：
  描述：

  (R)-3-Hydroxy-2-ureido-butyric acid 在 盐酸 、 sodium nitrite 作用下， 生成 D-threonine
  参考文献：
  名称：

  New hydantoinases from thermophilic microorganisms — Synthesis of enantiomerically pure D-amino acids

  摘要：

  A series of 14 D-alpha-amino acids were prepared in high chemical and optical yields from the corresponding racemic hydantoins by employing two novel hydantoinases from om thermophilic microorganisms.

  DOI：

  10.1016/0957-4166(95)00157-k

文献信息

• Selective inhibition of aggrecanase in osteoarthritis treatment
  申请人：Noe C. Mark

  公开号：US20050227997A1

  公开（公告）日：2005-10-13

  This invention relates to a method of treatment for osteoarthritis involving inhibitors of aggrecanase that demonstrate IC 50 s of less than 20 nM and demonstrate differential potency against matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinases (ADAMs or reprolysins). This invention also relates to compounds, methods of treatment and composition of Formula I: or a therapeutically acceptable salt thereof, wherein X is carbon or nitrogen; R 1 and R 2 are independently selected from the group consisting of hydrogen, hydroxy, and methyl, wherein at least one of R 1 and R 2 is methyl; R 3 and R 4 are independently selected from the group consisting of hydrogen, hydroxy, and methyl, or R 3 and R 4 may be taken together to form a carbonyl group; and R 5 and R 6 are independent substituents in the ortho, meta, or para positions and are independently selected from the group consisting of hydrogen, halogen, cyano, methyl, and ethyl; with the provisos: when X is carbon, then R 7 and R 8 are both hydrogen and at least one of R 1 , R 2 , R 3 , and R 4 is hydroxy; when X is carbon and R 5 is para-halo, then at least one of R 6 , R 3 , and R 4 is not hydrogen; when X is nitrogen, then R 8 is not present and R 7 is hydrogen or a group of the formula: wherein, Y is —CH 2 —NH 2 or —NH—CH 3 ; and when X is nitrogen and R 7 is H, then R 3 and R 4 are taken together to form a carbonyl group.

  这项发明涉及一种治疗骨关节炎的方法，涉及抑制aggrecanase的抑制剂，其IC50小于20 nM，并且对基质金属蛋白酶（MMPs）和脱粒蛋白酶（ADAMs或reprolysins）表现出差异的效力。这项发明还涉及化合物、治疗方法和Formula I的组成： 或其治疗上可接受的盐，其中X为碳或氮； R1和R2分别选自氢、羟基和甲基组成的群，其中至少一个为甲基； R3和R4分别选自氢、羟基和甲基组成的群，或R3和R4可一起形成一个羰基；以及 R5和R6是正交位、间位或对位的独立取代基，分别选自氢、卤素、氰基、甲基和乙基；附加条件： 当X为碳时，R7和R8都是氢，且至少一个R1、R2、R3和R4为羟基； 当X为碳且R5为对位卤素时，至少一个R6、R3和R4不是氢； 当X为氮时，R8不存在且R7为氢或一个公式的基团： 其中，Y为—CH2—NH2或—NH—CH3；以及 当X为氮且R7为H时，R3和R4一起形成一个羰基。
• Preparation of .beta.-lactams and intermediates therefor
  申请人：Gist-Brocades N.V.

  公开号：US04260743A1

  公开（公告）日：1981-04-07

  Novel process for the preparation of .beta.-lactams of the formulae: ##STR1## wherein R' represents lower alkyl, aryl or aryl (lower alkyl), R" represents hydrogen or lower alkyl or R' and R" together with the carbon atoms to which they are attached represent lower cycloalkyl, R'" represents lower alkyl or a group --OR, wherein R represents lower alkyl, X.sub.1, Y.sub.1 and Z.sub.1 are hydrogen or selected organic radicals and R.sub.1 represents an acyl group; which successively involves reacting an 1,3-dicarbonyl compound of the formula: ##STR2## with glycine in the presence of a base to form a vinylamino salt of the formula: ##STR3## wherein M.sub.1.sup.+ is the cation of the base, activating the carboxyl group of said vinylamino salt with an appropriate activating agent and reacting the activated compound in the presence of a tertiary base with an imino compound of the formula: ##STR4## to form the corresponding .alpha.-vinylamino-.beta.-lactam of formula IV A and if desired, subjecting said .beta.-lactam to mild acid hydrolysis to obtain the corresponding .alpha.-amino-.beta.-lactam of formula V A and if desired, acylating said .alpha.-amino-.beta.-lactam with an appropriate acylating agent to obtain a corresponding .alpha.-acylamino-.beta.-lactam of formula VI A.

  很抱歉，您似乎没有提供需要翻译成中文的文本。请提供文本内容，我将为您翻译成中文。
• Selective inhibitors of aggrecanase in osteoarthritis treatment
  申请人：Pfizer Products Inc.

  公开号：EP1081137A1

  公开（公告）日：2001-03-07

  This invention relates to a method of treatment for osteoarthritis involving inhibitors of aggrecanase that demonstrate IC50s of less than 20 nM and demonstrate differential potency against matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinases (ADAMs or reprolysins). This invention also relates to compounds, methods of treatment and composition of Formula I: or a therapeutically acceptable salt thereof, wherein X is carbon or nitrogen; R1 and R2 are independently selected from the group consisting of hydrogen, hydroxy, and methyl, wherein at least one of R1 and R2 is methyl; R3 and R4 are independently selected from the group consisting of hydrogen, hydroxy, and methyl, or R3 and R4 may be taken together to form a carbonyl group; and R5 and R6 are independent substituents in the ortho, meta, or para positions and are independently selected from the group consisting of hydrogen, halogen, cyano, methyl, and ethyl; with the provisos: when X is carbon, then R7 and R8 are both hydrogen and at least one of R1, R2, R3, and R4 is hydroxy; when X is carbon and R5 is para-halo, then at least one of R6, R3, and R4 is not hydrogen; when X is nitrogen, then R8 is not present and R7 is hydrogen or a group of the formula: wherein, Y is -CH2-NH2 or -NH-CH3; and when X is nitrogen and R7 is H, then R3 and R4 are taken together to form a carbonyl group.

  这项发明涉及一种治疗骨关节炎的方法，涉及抑制aggrecanase的方法，其IC50小于20 nM，并且对基质金属蛋白酶（MMPs）和脱粒蛋白酶（ADAMs或reprolysins）表现出差异的效力。该发明还涉及化合物、治疗方法和Formula I的组成： 或其治疗上可接受的盐，其中 X为碳或氮； R1和R2分别选自氢、羟基和甲基组成的群，其中至少一个为甲基； R3和R4分别选自氢、羟基和甲基组成的群，或R3和R4可一起形成羰基；以及 R5和R6是正交位、间位或对位的独立取代基，分别选自氢、卤素、氰基、甲基和乙基组成的群； 附加条件： 当X为碳时，R7和R8均为氢，且R1、R2、R3和R4中至少一个为羟基； 当X为碳且R5为对位卤素时，至少一个R6、R3和R4不是氢； 当X为氮时，R8不存在，R7为氢或下式的基团： 其中，Y为-CH2-NH2或-NH-CH3；以及 当X为氮且R7为H时，R3和R4一起形成羰基。
• Structural and NMR investigations of the ternary adducts of twenty α-amino acids and selected dipeptides with a chiral, diaqua–ytterbium complex
  作者：Rachel S. Dickins、Andrei S. Batsanov、Judith A. K. Howard、David Parker、Horst Puschmann、Stefania Salamano

  DOI：10.1039/b311791j

  日期：——

  A detailed investigation of the nature of the binding of each of the 20 common α-amino acids and various selected dipeptides to a chiral, diaqua–ytterbium complex in aqueous solution has been carried out. Analysis of the dipolar 1H NMR paramagnetic shifts suggests that the α-amino acids form a common chelated structure within a nine-coordinate mono-capped square antiprismatic coordination environment

  详细研究20种常见α-氨基酸与各种选择的氨基酸的结合性质 二肽在水溶液中制备了手性的dia- complex配合物。对偶极1 H NMR顺磁位移的分析表明，α-氨基酸在九坐标单峰方形反棱柱配位环境中形成了常见的螯合结构，胺N轴向布置。九种螯合YbL 1 –的晶体结构氨基酸 加合物（Gly，Ala，Ser， 苏氨酸，遇到了）确认这一点。三元配合物二肽（例如 甘氨酸， 甘氨酸， 甘氨酸， 甘氨酸， 甘氨酸， 甘氨酸， 蛋氨酸， 天冬氨酸， 他的甘氨酸）也偏爱航站楼 胺如轴向供体与邻近的酰胺基结合，生成五环螯合物。仅在N末端Asp的情况下才发现通过侧链功能螯合的证据。关于upon离子的手性环境氨基酸 还使用近红外探测了结合 圆二色光谱。
• Arylsulfonamido-substituted hydroxamic acids
  申请人：Ciba-Geigy Corporation

  公开号：US05455258A1

  公开（公告）日：1995-10-03

  Particularly the invention relates to the compounds of formula I ##STR1## (a) wherein Ar is carbocyclic or heterocyclic aryl; R is hydrogen, lower alkyl, carbocyclic aryl-lower alkyl, carbocyclic aryl, heterocyclic aryl, biaryl, biaryl-lower alkyl, heterocyclic aryl-lower alkyl, mono- or poly-halo-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl, C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, amino, mono- or di-lower alkylamino)-lower alkyl, acylamino-lower alkyl, (N-lower alkyl-piperazino or N-aryl-lower alkylpiperazino)-lower alkyl, or (morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl or N-lower alkylpiperidyl)-lower alkyl; R.sub.1 is hydrogen, lower alkyl, carbocyclic aryl-lower alkyl, carbocyclic aryl, heterocyclic aryl, biaryl, biaryl-lower alkyl, heterocyclic aryl-lower alkyl, mono- or poly-halo-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl, C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, (carbocyclic or heterocyclic aryl)-lower alkoxy-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, (amino, mono- or di-lower alkylamino)-lower alkyl, (N-lower alkyl-piperazino or N-aryl-lower alkylpiperazino)-lower alkyl, (morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl or N-lower alkylpiperidyl)-lower alkyl, acylamino-lower alkyl, piperidyl or N-lower alkylpiperidyl; R.sub.2 is hydrogen or lower alkyl; pharmaceutically acceptable prodrug derivatives; and pharmaceutically acceptable salts thereof.

  该发明涉及以下式I的化合物：(a)其中Ar是碳环或杂环芳基；R是氢、低烷基、碳环芳基-低烷基、碳环芳基、杂环芳基、联苯、联苯-低烷基、杂环芳基-低烷基、单取代或多取代卤代低烷基、C.sub.3-C.sub.7-环烷基、C.sub.3-C.sub.7-环烷基-低烷基、羟基-低烷基、酰氧基-低烷基、低烷氧基-低烷基、低烷基-(硫、亚砜或砜基)-低烷基、氨基、单取代或双取代低烷氨基)-低烷基、酰胺基-低烷基、(N-低烷基哌嗪基或N-芳基-低烷基哌嗪基)-低烷基，或(morpholino、硫代吗啉、哌啶基、吡咯啶基、哌啶基或N-低烷基哌啶基)-低烷基；R.sub.1是氢、低烷基、碳环芳基-低烷基、碳环芳基、杂环芳基、联苯、联苯-低烷基、杂环芳基-低烷基、单取代或多取代卤代低烷基、C.sub.3-C.sub.7-环烷基、C.sub.3-C.sub.7-环烷基-低烷基、羟基-低烷基、酰氧基-低烷基、低烷氧基-低烷基、(碳环或杂环芳基)-低烷氧基-低烷基、低烷基-(硫、亚砜或砜基)-低烷基、(氨基、单取代或双取代低烷氨基)-低烷基、(N-低烷基哌嗪基或N-芳基-低烷基哌嗪基)-低烷基、(morpholino、硫代吗啉、哌啶基、吡咯啶基、哌啶基或N-低烷基哌啶基)-低烷基、酰胺基-低烷基、哌啶基或N-低烷基哌啶基；R.sub.2是氢或低烷基；药学上可接受的前药衍生物；及其药学上可接受的盐。